Peripheral precocious puberty

Interventions to improve growth

Nadine G. Haddad, Erica Eugster

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Precocious puberty is usually defined as the onset of secondary sexual characteristics prior to age 7 1/2-8 in girls and prior to age 9 in boys. Although sex steroids cause growth acceleration and tall stature in the short term, the potential for a significant loss of ultimate adult height is a central concern in all children with pathologic forms of early puberty. Unlike central precocious puberty (CPP), which refers to early activation of the hypothalamic-pituitary-gonadal axis, peripheral precocious puberty (PPP) arises from abnormal sex steroid exposure from other sources. These may be endogenous or exogenous, congenital, or acquired. The clinical presentation will depend on the underlying process and on the class of sex steroids (estrogens or androgens) involved. Although many different causes of PPP exist, the most common are congenital adrenal hyperplasia (CAH), familial male-limited precocious puberty (FMPP), and McCune Albright syndrome (MAS). The pathophysiology and clinical characteristics of each of these will be described. A variety of factors are known to influence growth in these disorders. The impact of primary and adjuvant treatment on growth and ultimate height in children with these conditions will be discussed. Data regarding the long-term outcome of established clinical management as well as preliminary findings from investigational approaches will also be summarized.

Original languageEnglish (US)
Title of host publicationHandbook of Growth and Growth Monitoring in Health and Disease
PublisherSpringer New York
Pages1199-1212
Number of pages14
ISBN (Electronic)9781441917959
ISBN (Print)9781441917942
DOIs
StatePublished - Jan 1 2012

Fingerprint

Precocious Puberty
Steroids
Growth
Polyostotic Fibrous Dysplasia
Growth Disorders
Congenital Adrenal Hyperplasia
Puberty
Androgens
Estrogens
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Haddad, N. G., & Eugster, E. (2012). Peripheral precocious puberty: Interventions to improve growth. In Handbook of Growth and Growth Monitoring in Health and Disease (pp. 1199-1212). Springer New York. https://doi.org/10.1007/978-1-4419-1795-9_71

Peripheral precocious puberty : Interventions to improve growth. / Haddad, Nadine G.; Eugster, Erica.

Handbook of Growth and Growth Monitoring in Health and Disease. Springer New York, 2012. p. 1199-1212.

Research output: Chapter in Book/Report/Conference proceedingChapter

Haddad, NG & Eugster, E 2012, Peripheral precocious puberty: Interventions to improve growth. in Handbook of Growth and Growth Monitoring in Health and Disease. Springer New York, pp. 1199-1212. https://doi.org/10.1007/978-1-4419-1795-9_71
Haddad NG, Eugster E. Peripheral precocious puberty: Interventions to improve growth. In Handbook of Growth and Growth Monitoring in Health and Disease. Springer New York. 2012. p. 1199-1212 https://doi.org/10.1007/978-1-4419-1795-9_71
Haddad, Nadine G. ; Eugster, Erica. / Peripheral precocious puberty : Interventions to improve growth. Handbook of Growth and Growth Monitoring in Health and Disease. Springer New York, 2012. pp. 1199-1212
@inbook{a4be8fa804a84e08a7af6ad5dec02ed4,
title = "Peripheral precocious puberty: Interventions to improve growth",
abstract = "Precocious puberty is usually defined as the onset of secondary sexual characteristics prior to age 7 1/2-8 in girls and prior to age 9 in boys. Although sex steroids cause growth acceleration and tall stature in the short term, the potential for a significant loss of ultimate adult height is a central concern in all children with pathologic forms of early puberty. Unlike central precocious puberty (CPP), which refers to early activation of the hypothalamic-pituitary-gonadal axis, peripheral precocious puberty (PPP) arises from abnormal sex steroid exposure from other sources. These may be endogenous or exogenous, congenital, or acquired. The clinical presentation will depend on the underlying process and on the class of sex steroids (estrogens or androgens) involved. Although many different causes of PPP exist, the most common are congenital adrenal hyperplasia (CAH), familial male-limited precocious puberty (FMPP), and McCune Albright syndrome (MAS). The pathophysiology and clinical characteristics of each of these will be described. A variety of factors are known to influence growth in these disorders. The impact of primary and adjuvant treatment on growth and ultimate height in children with these conditions will be discussed. Data regarding the long-term outcome of established clinical management as well as preliminary findings from investigational approaches will also be summarized.",
author = "Haddad, {Nadine G.} and Erica Eugster",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-1795-9_71",
language = "English (US)",
isbn = "9781441917942",
pages = "1199--1212",
booktitle = "Handbook of Growth and Growth Monitoring in Health and Disease",
publisher = "Springer New York",

}

TY - CHAP

T1 - Peripheral precocious puberty

T2 - Interventions to improve growth

AU - Haddad, Nadine G.

AU - Eugster, Erica

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Precocious puberty is usually defined as the onset of secondary sexual characteristics prior to age 7 1/2-8 in girls and prior to age 9 in boys. Although sex steroids cause growth acceleration and tall stature in the short term, the potential for a significant loss of ultimate adult height is a central concern in all children with pathologic forms of early puberty. Unlike central precocious puberty (CPP), which refers to early activation of the hypothalamic-pituitary-gonadal axis, peripheral precocious puberty (PPP) arises from abnormal sex steroid exposure from other sources. These may be endogenous or exogenous, congenital, or acquired. The clinical presentation will depend on the underlying process and on the class of sex steroids (estrogens or androgens) involved. Although many different causes of PPP exist, the most common are congenital adrenal hyperplasia (CAH), familial male-limited precocious puberty (FMPP), and McCune Albright syndrome (MAS). The pathophysiology and clinical characteristics of each of these will be described. A variety of factors are known to influence growth in these disorders. The impact of primary and adjuvant treatment on growth and ultimate height in children with these conditions will be discussed. Data regarding the long-term outcome of established clinical management as well as preliminary findings from investigational approaches will also be summarized.

AB - Precocious puberty is usually defined as the onset of secondary sexual characteristics prior to age 7 1/2-8 in girls and prior to age 9 in boys. Although sex steroids cause growth acceleration and tall stature in the short term, the potential for a significant loss of ultimate adult height is a central concern in all children with pathologic forms of early puberty. Unlike central precocious puberty (CPP), which refers to early activation of the hypothalamic-pituitary-gonadal axis, peripheral precocious puberty (PPP) arises from abnormal sex steroid exposure from other sources. These may be endogenous or exogenous, congenital, or acquired. The clinical presentation will depend on the underlying process and on the class of sex steroids (estrogens or androgens) involved. Although many different causes of PPP exist, the most common are congenital adrenal hyperplasia (CAH), familial male-limited precocious puberty (FMPP), and McCune Albright syndrome (MAS). The pathophysiology and clinical characteristics of each of these will be described. A variety of factors are known to influence growth in these disorders. The impact of primary and adjuvant treatment on growth and ultimate height in children with these conditions will be discussed. Data regarding the long-term outcome of established clinical management as well as preliminary findings from investigational approaches will also be summarized.

UR - http://www.scopus.com/inward/record.url?scp=85025608980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025608980&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1795-9_71

DO - 10.1007/978-1-4419-1795-9_71

M3 - Chapter

SN - 9781441917942

SP - 1199

EP - 1212

BT - Handbook of Growth and Growth Monitoring in Health and Disease

PB - Springer New York

ER -